Neoantigens Market Size, Share, and Growth 2024-2028
Neoantigens Market: Strategic Insights
Neoantigens Market
-
CAGR (2023 - 2028)31.2% -
Market Size 2023
US$ 271.43 Million -
Market Size 2028
US$ 1,054.78 Million
Market Dynamics
GROWTH DRIVERS
- Biotechnology developments increasing
- Cancer driving personalized immunotherapies
- Advances in genomic sequencing enhancing therapies
FUTURE TRENDS
- Development of AI and machine learning tools for more efficient neoantigen prediction and identification.
- Increasing use of combination therapies incorporating neoantigens with checkpoint inhibitors for enhanced efficacy.
- Advancements in personalized vaccine platforms using neoantigens to boost immune responses in cancer patients.
OPPORTUNITIES
- Expansion of collaborations between biotech firms and academic institutions for neoantigen discovery and validation.
- Rising interest in neoantigen vaccines and therapeutic approaches as adjuncts to existing cancer treatments.
- Potential for application in autoimmune diseases and other therapeutic areas leveraging neoantigen targeting.
Key Players
- Achilles Therapeutics plc
- Advaxis Inc
- Frame Cancer Therapeutics
- Genocea
- Gradalis Inc
- Gritstone Oncology
- Immunicum AB
- Medigene AG
- Ziopharm Oncology Inc
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
Treatment - Combination Therapy and Mono Therapy
Therapeutic Specialty - Gastrointestinal Cancer
- Lung Cancer
- Solid Tumor
- Urinary Systems Cancers
- Melanoma
- Head and Neck Cancer
Get Free Sample For